Duchenne Muscular Dystrophy
Clinical research at the University of Manchester includes neuromuscular disease with a focus on Duchenne Muscular Dystrophy, reflecting interest in inherited disorders that affect skeletal muscle function and progressive weakness.
- dystrophin restoration
- exon skipping
- autologous mesoangioblasts
The sponsor’s activity in this area centers on therapies aimed at correcting the underlying genetic defect and supporting muscle-specific treatment strategies.
Genetic Therapy and Cell-Based Muscle Repair
The trial portfolio also covers gene therapy and cell-based regenerative medicine, with research directed toward restoring protein expression in affected muscle tissue after genetic modification of patient-derived cells.
- lentiviral vector engineering
- skeletal muscle injection
- muscle regeneration
This area highlights therapeutic interest in precision approaches for inherited muscular disorders and localized delivery to diseased muscle.
Breast Cancer Prevention
Another key research domain is breast cancer prevention, particularly in women with inherited cancer susceptibility, where the sponsor is involved in studies targeting risk reduction before malignancy develops.
- invasive breast cancer
- ductal carcinoma in situ
- cancer risk reduction
The research focus includes prevention strategies for individuals with a strong hereditary predisposition to breast cancer.
BRCA1-Associated Hereditary Cancer Risk
The sponsor is active in research involving BRCA1 germline mutation carriers, addressing inherited susceptibility to breast cancer and the medical management of women at elevated genetic risk.
- hereditary cancer syndromes
- genetic predisposition
- preventive oncology
This therapeutic domain connects oncology with inherited-risk screening and preventive intervention research.
